In cases where MGPT failed to detect a PV, tumor tissue-based methylation assay targeting the MLH1 promoter as well as RNA-based analysis of allelic imbalance were conducted to select high-risk samples for WGS. This evidence concerns the gene MLH1 and neoplasm.